MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC5028326 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature